<!DOCTYPE html>
        <html lang="en">
        <head>
          <meta charset="UTF-8" />
          <meta name="viewport" content="width=device-width, initial-scale=1.0" />
          <title>MinMaxMuscle | Melanotan II</title>
          <meta name="description" content="Curated source summaries for Melanotan II." />
          <link rel="stylesheet" href="../assets/css/style.css" />
        </head>
        <body>
          <header>
            <div class="nav-container">
              <div class="logo">
                <img src="../assets/img/logo.png" alt="MinMaxMuscle Logo" />
                <span>MINMAXMUSCLE</span>
              </div>
              <nav class="desktop-nav">
                <a href="../index.html">Home</a>
                <a href="../training.html">Training</a>
                <a href="../nutrition.html">Nutrition</a>
                <a href="../peptides.html">Peptides</a>
                <a href="../coaching.html">Coaching</a>
                <a href="../contact.html">Contact</a>
              </nav>
              <div class="hamburger" id="hamburger">
                <span></span>
                <span></span>
                <span></span>
              </div>
            </div>
            <div class="mobile-menu" id="mobileMenu">
              <a href="../index.html">Home</a>
              <a href="../training.html">Training</a>
              <a href="../nutrition.html">Nutrition</a>
              <a href="../peptides.html">Peptides</a>
              <a href="../coaching.html">Coaching</a>
              <a href="../contact.html">Contact</a>
            </div>
          </header>
          <main>
            <section class="hero">
              <h1>Melanotan II</h1>
              <p>Automated source summaries for educational review. Verify claims with qualified professionals.</p>
            </section>
            <section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://en.wikipedia.org/wiki/Melanotan_II" rel="noopener noreferrer" target="_blank">https://en.wikipedia.org/wiki/Melanotan_II</a></p>
  <ul>
    <li>Main page</li><li>Contents</li><li>Current events</li><li>Random article</li><li>About Wikipedia</li><li>Contact us</li><li>Help</li><li>Learn to edit</li><li>Community portal</li><li>Recent changes</li><li>Upload file</li><li>Special pages</li><li>Donate</li><li>Create account</li><li>Log in</li><li># Contents</li><li>(Top)</li><li>1 Synthesis</li><li>2 Mechanism of action</li><li>3 History and research</li><li>4 Society and culture</li><li>5 See also</li><li>6 References</li><li># Melanotan II</li><li>تۆرکجه</li><li>Dansk</li><li>Deutsch</li><li>Español</li><li>فارسی</li><li>Nederlands</li><li>Norsk bokmål</li><li>Саха тыла</li><li>Српски / srpski</li><li>Srpskohrvatski / српскохрватски</li><li>Svenska</li><li>Tiếng Việt</li><li>中文</li><li>Article</li><li>Talk</li><li>Read</li><li>Edit</li><li>View history</li><li>What links here</li><li>Related changes</li><li>Permanent link</li><li>Page information</li><li>Cite this page</li><li>Get shortened URL</li><li>Download QR code</li><li>Download as PDF</li><li>Printable version</li><li>Wikidata item</li><li>Ac-Nle-cyclo[Asp-His- D -Phe-Arg-Trp-Lys]-NH 2</li><li>Ac-Nle-c[Asp-His- D -Phe-Arg-Trp-Lys]-NH 2</li><li>Ac-cyclo[Nle 4 , Asp 5 , D -Phe 7 , Lys 10 ]α-MSH 4–10 -NH 2</li><li>N -Acetyl- L -norleucyl- L -α-aspartyl- L -histidyl- D -phenylalanyl- L -arginyl- L -tryptophyl- L -lysinamide (2→7)-lactam</li><li>MT-II</li><li>121062-08-6 N</li><li>Interactive image</li><li>ChEMBL430239 Y</li><li>83450 Y</li><li>1323</li><li>92432</li><li>UPF5CJ93X7 Y</li><li>DTXSID90153135</li><li>InChI=1S/C50H69N15O9/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56)/t35-,36-,37-,38+,39-,40-,41-/m0/s1 Y Key: JDKLPDJLXHXHNV-MFVUMRCOSA-N Y</li><li>CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N)NC(=O)C</li><li>Melanotan II is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH) that stimulates melanogenesis to facilitate tanning. It may also increase sexual arousal.</li><li>It was developed as a successor to afamelanotide ("Melanotan I"), an FDA -approved drug operating through a similar pathway. Clinuvel Pharmaceuticals intended to offer it as a cosmetic, but abandoned this pursuit in the 2000s due to regulatory restrictions and concerns about the promotion of suntanning. Unlicensed Melanotan II is found on the internet, although health agencies advise against its use due to lack of testing and regulatory approval.</li><li>Melanotan-II may cause reversible darkening of moles and freckles. It is unclear if Melanotan II can increase (or reduce) the risk of developing melanoma , because reports of melanomas associated with its use have coincided with heavy UV exposure and sun bed use. [ 1 ] [ 2 ] A 2013 scientific review found there was no conclusive evidence it causes melanoma, [ 1 ] and a 2021 review concluded "the increased risk of melanoma in Melanotan users, who use it for tanning and exhibit sun-seeking behaviour, can probably be explained by more UV exposure". [ 2 ]</li><li>Side effects may include facial flushing, nausea and erection in males.</li><li># Synthesis</li><li>In the synthesis of melanotan II, an ε-amino group of lysine and an γ-carboxy group of aspartic acid have their orthogonal protection removed before undergoing a carbodiimide mediated lactamization, leading to an intermediate. This intermediate, when attached to N-acetylnorleucine, forms melanotan II. The entire process can be accomplished in 12 steps with an overall yield of 2.6%, and the product is more than 90% pure without preparative chromatography. [ 3 ]</li><li># Mechanism of action</li><li>Melanotan II acts as a non-selective agonist of the melanocortin receptors MC 1 , MC 3 , MC 4 , and MC 5 . [ 4 ]</li><li>Melanotan II produces melanogenesis by activation of the MC 1 receptor, whereas its clinically documented sexual effects are thought to be related to its ability to activate the MC 4 receptor (though the MC 3 is thought to also possibly be involved). [ 5 ] [ 6 ]</li><li>Other effects of melanotan II, mostly regarded as adverse effects , include flushing , nausea , vomiting , stretching , yawning , and loss of appetite (the last via activation of MC 4 ). [ 7 ] [ 8 ]</li><li># History and research</li><li>Research in the early 1960s showed that in rats, administration of α-MSH caused sexual arousal, and work on this continued in many labs up through the 1980s, when scientists at the University of Arizona began attempting to develop α-MSH and analogs as potential sunless tanning agents, and synthesized and tested several analogs, including melanotan-I and melanotan II. [ 6 ] [ 9 ]</li><li>Early in the research process one of the scientists, who was conducting experiments on himself with an early tool compound, melanotan II, injected himself with twice the dose he intended to and got an eight-hour erection, along with nausea and vomiting. [ 6 ] [ non-primary source needed ]</li><li>As a tanning agent, melanotan I (now known as afamelanotide ) was licensed by Competitive Technologies, a technology transfer company operating on behalf of the University of Arizona, to an Australian startup called Epitan, [ 10 ] [ 11 ] which changed its name to Clinuvel in 2006. [ 12 ] Afamelanotide was approved by the FDA in 2019. [ 2 ]</li><li>As a sexual dysfunction agent, melanotan II was licensed by Competitive Technologies to Palatin Technologies. [ 9 ] Palatin ceased development of melanotan II in 2000 and synthesized, patented, and began to develop bremelanotide , a likely metabolite of melanotan II that differs in that it has a carboxy group where melanotan II has an amide . [ 6 ] [ 13 ]</li><li>Clinuvel Pharmaceuticals intended to offer it as a cosmetic, but abandoned this pursuit in the 2000s. [ 14 ]</li><li>Competitive Technologies (Clinuvel) sued Palatin for breach of contract and tried to claim ownership of bremelanotide; [ 13 ] the parties settled in 2008 with Palatin retaining rights to bremelanotide, returning rights to melanotan II to Competitive Technologies, and paying US$800,000. [ 15 ]</li><li>Melanotan-II may cause reversible darkening of moles and freckles. It is unclear if Melanotan II can increase (or reduce) the risk of developing melanoma . Reports of melanomas associated with the use of Melanotan II have coincided with heavy sunbathing and sun bed use. [ 1 ] [ 2 ] A 2013 scientific review found there was no conclusive evidence it causes melanoma, [ 1 ] and a 2021 review concluded "the increased risk of melanoma in Melanotan users, who use it for tanning and exhibit sun-seeking behaviour, can probably be explained by more UV exposure". [ 2 ] A 2020 in vivo study found that Melanotan II suppressed the progression of melanomas. [ 16 ]</li><li>A 2019 study showed Melanotan-II having improved sociability deficits in mice exhibiting autistic features. [ 17 ]</li><li># Society and culture</li><li>Numerous products are sold online and in gyms and beauty salons as "melanotan" or "melanotan-1", "melanotan-2" or "Barbie drug" in their marketing. [ 18 ] [ 19 ] [ 20 ] [ 21 ] Sale of these products for human use is illegal in many jurisdictions. [ 22 ] [ 23 ] [ 24 ] [ 25 ]</li><li>Starting in 2007, health agencies in various countries began issuing warnings against their use. [ 26 ] [ 27 ] [ 28 ] [ 29 ] [ 30 ] [ 31 ]</li><li># See also</li><li>Decapaptide-12</li><li>Methoxsalen</li><li># References</li><li>^ a b c d .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}} Javed, Muhammad; Yarrow, Jeremy; Hemington gorse, Sarah (2013-10-01). "Does melanotan injections (TAN JAB) cause melanoma? A systemic review of the effects of melanotan injections" . International Journal of Surgery . 11 (8): 677. doi : 10.1016/j.ijsu.2013.06.485 . ISSN 1743-9191 .</li><li>^ a b c d e Wensink, Debby; Wagenmakers, Margreet A.E.M.; Langendonk, Janneke G. (2021-02-01). "Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria" . Expert Review of Clinical Pharmacology . 14 (2): 151– 160. doi : 10.1080/17512433.2021.1879638 . ISSN 1751-2433 . PMID 33507118 .</li><li>^ Ryakhovsky, Vladimir V; Khachiyan, Georgy A; Kosovova, Nina F; Isamiddinova, Elena F; Ivanov, Andrey S (30 October 2008). "The first preparative solution phase synthesis of melanotan II" . Beilstein Journal of Organic Chemistry . 4 : 39. doi : 10.3762/bjoc.4.39 . PMC 2587946 . PMID 19043625 .</li><li>^ Wikberg JE (2001). "Melanocortin receptors: new opportunities in drug discovery". Expert Opinion on Therapeutic Patents . 11 (1): 61– 76. doi : 10.1517/13543776.11.1.61 . ISSN 1354-3776 . S2CID 86254068 .</li><li>^ Norris DO, Lopez KH (25 November 2010). Hormones and Reproduction of Vertebrates . Academic Press. pp. 4–. ISBN 978-0-08-095809-5 .</li><li>^ a b c d King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H (2007). "Melanocortin receptors, melanotropic peptides and penile erection" . Curr Top Med Chem . 7 (11): 1098– 1106. doi : 10.2174/1568026610707011111 . PMC 2694735 . PMID 17584130 .</li><li>^ Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction: Two-Volume Set . Academic Press. pp. 2230–. ISBN 978-0-12-397769-4 .</li><li>^ Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (28 September 2011). Campbell-Walsh Urology . Elsevier Health Sciences. pp. 743–. ISBN 978-1-4557-2298-3 .</li><li>^ a b Hadley ME (October 2005). "Discovery that a melanocortin regulates sexual functions in male and female humans". Peptides . 26 (10): 1687– 9. doi : 10.1016/j.peptides.2005.01.023 . PMID 15996790 . S2CID 22559801 .</li><li>^ "EpiTan focuses on Melanotan, a potential blockbuster" . The Pharma Letter . 1 November 2004.</li><li>^ Hadley ME, Dorr RT (April 2006). "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization". Peptides . 27 (4): 921– 30. doi : 10.1016/j.peptides.2005.01.029 . PMID 16412534 . S2CID 21025287 .</li><li>^ "Epitan changes name to Clinuvel, announces new clinical program" . LabOnline . 27 February 2006.</li><li>^ a b "Press Release: Palatin Technologies Refutes Competitive Technologies Contention of Material Breach" . Palatin Technologies via PR Newswire . September 12, 2007. Archived from the original on 7 April 2017.</li><li>^ Madrigal, Alexis (2024-03-07). "Suntan Drug Greenlighted for Trials | WIRED" . Wired . Archived from the original on 7 March 2024 . Retrieved 2025-01-21 .</li><li>^ "Press Release: Palatin Technologies Announces Litigation Settlement With Competitive Technologies" . Palatin Technologies via PR Newswire . January 22, 2008.</li><li>^ Wu, Jian-Ching; Tsai, Han-En; Hsiao, Yi-Hsiang; Wu, Ji-Syuan; Wu, Chieh-Shan; Tai, Ming-Hong (2020-01-20). "Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition" . International Journal of Molecular Sciences . 21 (2): 681. doi : 10.3390/ijms21020681 . PMC 7013727 . PMID 31968661 .</li><li>^ Minakova, Elena; Lang, Jordan; Medel-Matus, Jesus-Servando; Gould, Georgianna G.; Reynolds, Ashley; Shin, Don; Mazarati, Andrey; Sankar, Raman (2019). "Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism" . PLOS ONE . 14 (1) e0210389. Bibcode : 2019PLoSO..1410389M . doi : 10.1371/journal.pone.0210389 . ISSN 1932-6203 . PMC 6328175 . PMID 30629642 .</li><li>^ "Believe It Or Not 'Tanorexia' A Very Real Problem" . WCBS-TV , CBS . 2009-05-20. Archived from the original on May 21, 2009 . Retrieved 2009-07-23 .</li><li>^ "Fools Gold" . Cosmopolitan (Australia). 2009-06-14. Archived from the original on 2009-09-12 . Retrieved 2009-07-25 .</li><li>^ Madrigal A (2009-01-29). "Suntan Drug Greenlighted for Trials" . Wired . Archived from the original on 5 May 2009 . Retrieved 2009-04-11 .</li><li>^ Habbema, Louis; Halk, Anne Berthe; Neumann, Martino; Bergman, Wilma (2017-03-17). "Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review" . International Journal of Dermatology . 56 (10): 975– 980. doi : 10.1111/ijd.13585 . ISSN 0011-9059 .</li><li>^ "Tanning drug a health risk" . Herald Sun . 2009-10-31. Archived from the original on 2010-12-29 . Retrieved 2009-10-31 .</li><li>^ Langan EA, Nie Z, Rhodes LE (September 2010). "Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?". The British Journal of Dermatology . 163 (3): 451– 5. doi : 10.1111/j.1365-2133.2010.09891.x . PMID 20545686 . S2CID 8203334 .</li><li>^ Langan EA, Ramlogan D, Jamieson LA, Rhodes LE (January 2009). "Change in moles linked to use of unlicensed "sun tan jab" ". BMJ . 338 : b277. doi : 10.1136/bmj.b277 . PMID 19174439 . S2CID 27838904 .</li><li>^ "Risky tan jab warnings 'ignored' " . BBC . 2009-02-18. Archived from the original on 21 February 2009 . Retrieved 2009-03-04 .</li><li>^ "Warning against the product Melanotan" . Danish Medicines Agency . 2008 . Retrieved 2008-08-11 .</li><li>^ " "Tan jab" is an unlicensed medicine and may not be safe" . MHRA . 2008. Archived from the original on 2008-12-18 . Retrieved 2008-11-17 .</li><li>^ "US Lab Research Inc Warning letter" . U.S. Food and Drug Administration . 2009-01-29. Archived from the original on 10 July 2009 . Retrieved 2009-07-23 .</li><li>^ "Melanotan Powder for Injection" . Notice Information: – Warning – 27 February 2009 . Irish Medicines Board . 2009 . Retrieved 2009-02-02 .</li><li>^ "Legemiddelverket advarer mot bruk av Melanotan" . Norwegian Medicines Agency. 2007-12-13. Archived from the original on 17 April 2009 . Retrieved 2009-03-11 .</li><li>^ "Melanotan – farlig og ulovlig brunfarge" . Norwegian Medicines Agency . 2009-01-23. Archived from the original on 17 April 2009 . Retrieved 2009-03-11 .</li><li>v</li><li>t</li><li>e</li><li>Agonists: ACTH (corticotropin)</li><li>Afamelanotide (melanotan I)</li><li>BMS-470539</li><li>Bremelanotide</li><li>HS-014</li><li>HS-024</li><li>MSH ( α , β , γ )</li><li>Melanotan II</li><li>Modimelanotide</li><li>PL-8177</li><li>SHU-8914</li><li>SHU-9005</li><li>SHU-9119</li><li>SNAP-7941</li><li>Antagonists: ASIP</li><li>Alsactide</li><li>Codactide</li><li>Giractide</li><li>Norleusactide (pentacosactride)</li><li>Seractide</li><li>Tetracosactide (tetracosactrin, cosyntropin)</li><li>Tosactide (octacosactrin)</li><li>Tricosactide</li><li>Tridecactide</li><li>Antagonists: Atumelnant (CRN04894)</li><li>PG-931</li><li>Antagonists: AGRP</li><li>ASIP</li><li>Mifomelatide (TCMCB07)</li><li>ML-00253764</li><li>PG-106</li><li>AZD2820</li><li>BIM-22493</li><li>Bivamelagon (LB54640)</li><li>LY-2112688</li><li>MK-0493</li><li>PF-00446687</li><li>PL-6983</li><li>Ro 27-3225</li><li>Setmelanotide</li><li>THIQ</li><li>HS-131</li><li>JKC-363</li><li>MCL-0020</li><li>MCL-0042</li><li>MCL-0129</li><li>MPB-10</li><li>Unknown: Semax</li><li>Agonists: Alsactide</li><li>Dersimelagon</li><li>Propeptides: Lipotropin ( β , γ )</li><li>N-POMC (NPP, pro-γ-MSH)</li><li>Proopiomelanocortin (POMC)</li><li>Melanocortin receptor agonists</li><li>Peptides</li><li>Abandoned drugs</li><li>Aphrodisiacs</li><li>Pages using the Phonos extension</li><li>Articles with short description</li><li>Short description is different from Wikidata</li><li>Pages including recorded pronunciations</li><li>Articles without InChI source</li><li>Articles without KEGG source</li><li>Articles with changed CASNo identifier</li><li>Articles containing unverified chemical infoboxes</li><li>Chembox image size set</li><li>Short description matches Wikidata</li><li>All pages needing factual verification</li><li>Wikipedia articles needing factual verification from January 2025</li><li>This page was last edited on 21 December 2025, at 16:35 (UTC) .</li><li>Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.</li><li>Privacy policy</li><li>Disclaimers</li><li>Contact Wikipedia</li><li>Legal & safety contacts</li><li>Code of Conduct</li><li>Developers</li><li>Statistics</li><li>Cookie statement</li><li>Mobile view</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Melanotan-II" rel="noopener noreferrer" target="_blank">https://pubchem.ncbi.nlm.nih.gov/compound/Melanotan-II</a></p>
  <ul>
    <li># JavaScript is required...</li><li>Please enable Javascript in order to use PubChem website.</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubmed.ncbi.nlm.nih.gov/16105018/" rel="noopener noreferrer" target="_blank">https://pubmed.ncbi.nlm.nih.gov/16105018/</a></p>
  <ul>
    <li># Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope</li><li># Authors</li><li># Affiliation</li><li>1 Department of Electrocardiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico. manliomarquez@yahoo.com</li><li>PMID: 16105018</li><li>DOI: 10.1111/j.1540-8159.2005.00183.x</li><li># Abstract</li><li>A 37-year-old man with Brugada syndrome (BrS) and arrhythmic storm is described. One month after implantation of a cardioverter-defibrillator he presented with recurrent appropriate shocks for spontaneous ventricular fibrillation (VF). Because of this arrhythmic storm, quinidine therapy was initiated with total suppression of all spontaneous arrhythmias. He had remained free of arrhythmias for 22 months since quinidine initiation. Two episodes of VF occurred after the patient stopped taking the medication. The patient resumed quinidine and has been free of VF for the last 3 months. This response to quinidine in a patient with symptomatic BrS supports its role in the prophylaxis of arrhythmic events in BrS.</li><li># MeSH terms</li><li>Adult</li><li>Anti-Arrhythmia Agents / therapeutic use*</li><li>Death, Sudden, Cardiac / prevention & control</li><li>Defibrillators, Implantable</li><li>Electric Countershock</li><li>Electrocardiography</li><li>Humans</li><li>Male</li><li>Quinidine / therapeutic use*</li><li>Syncope, Vasovagal / complications</li><li>Syncope, Vasovagal / physiopathology</li><li>Syncope, Vasovagal / therapy*</li><li>Syndrome</li><li>Ventricular Fibrillation / complications</li><li>Ventricular Fibrillation / physiopathology</li><li>Ventricular Fibrillation / therapy*</li><li># Substances</li><li>Anti-Arrhythmia Agents</li><li>Quinidine</li>
  </ul>
</section>
            <p class="disclaimer-link"><small>Back to the main peptide list: <a href="../peptides.html">Peptides Overview</a>.</small></p>
          </main>
          <footer>
            © MinMaxMuscle. Discipline builds the body. Systems keep it.
          </footer>
          <script src="../assets/js/script.js"></script>
        </body>
        </html>
